drugset / Trial / NCT04616209
Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Phase 1/2
Recruiting
24 enrolled
Precision Biotech Taiwan Corp.
Tri-Service General Hospital (TSGH) · collab
NaSequentialOpen-labelTreatment
Summary
Objectives: To determine the safety, tolerability, and efficacy of allogeneic PB103 in patients with IIIb/IV or refractory non-small-cell lung cancer
Timeline
- Start
- 2020-11-15
- Primary completion
- 2027-12-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PB103 | Cell therapy | 5e+08 cells | — |
| Subject | PB103 | Cell therapy | 1e+09 cells | — |
| Subject | PB103 | Cell therapy | 1.5e+09 cells | — |